<DOC>
	<DOCNO>NCT01066689</DOCNO>
	<brief_summary>Assessing impact J12 curative treatment rituximab ( 375 mg / mÂ² J5 ) base composite `` TREATMENT FAILURE ''</brief_summary>
	<brief_title>Impact Treatment With Rituximab Progression Humoral Acute Rejection After Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patient adult male female ( age 18 year ) , kidney transplantation le one year ( transplant living donor decease ) , acute humoral rejection define : The deterioration renal function assess serum creatinine increase 20 % compare best value , OR In first 28 day transplantation , significant creatinine decrease , AND At least 2 3 follow criterion : tissue damage ( ) acute tubular necrosis , ( b ) presence monocyte granulocytes CPT / glomerulus / capillary thrombosis , ( c ) intimal arteritis / fibrinoid necrosis C4d level CPT / presence Ig complement lesion fibrinoid necrosis Presence HLA antibody direct donor . Patient give write consent participate clinical trial . Pregnant lactate Women reproductive year without effective contraception , A patient multiple organ transplant , Patients clinically active infection HCV uncontrolled Patients active infection , suspect infection HIV HBV , tuberculosis , Patients heart failure class IV ( NYHA ) cardiac disease uncontrolled Patients vaccination schedule , Patient disabilities allow understand requirement test Patient safeguarding justice , guardianship trusteeship , Patient consindication rituximab ( know hypersensitivity component murine protein ) Patient previously receive rituximab within 3 month inclusion Patient participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>kidney transplantation , acute humoral rejection , rituximab</keyword>
</DOC>